- Pure Extracts trading on CSE under “PULL” symbol
- Pure Extracts cannabis and hemp industry verticals include toll processing, white labeling and developing its own private label of cannabis products
- Pure Extracts is entering the functional mushroom market
- Company’s CO2 extraction facility complies with European Union GMP standards – intends to seek EU GMP certification for exports to Europe
Pure Extracts Technologies (CSE: PULL), a plant-based extraction company focused on the cannabis, hemp, and functional mushroom sectors, recently announced that the Company’s stock is now trading on the Canadian Securities Exchange (“CSE”) under the symbol “PULL”.
“Our trading debut on the CSE is another vote of confidence in our ability to effectively meet the needs of consumers focused on receiving cannabis, hemp and functional mushroom products,” said Pure Extracts’ Chief Executive Officer Ben Nikolaevsky (
https://ibn.fm/wRim3).
Mainstream science is starting to prove what users have known for years – that functional mushrooms and cannabis-based products can help treat symptoms associated with a variety of physical and mental conditions. Pure Extracts is ahead of the curve in leveraging the market for plant-based medicines on a global scale through a strategy focused on product development, facility expansion, license procurement and product marketing.
“There currently is tremendous consumer demand for natural health products with the ability to immediately enhance our quality of life,” said Nikolaevsky. “With Health Canada officially granting Pure Extracts a Standard Processing License under the Cannabis Act, this has put us on a path to deliver full-spectrum oil products by the end of Q4, 2020.”
Interest in plant medicines has increased in the scientific community in recent years, particularly regarding the anti-inflammatory effects associated with cannabis (
https://ibn.fm/7g4vs) and the ability of cannabidiol (“CBD”) to relieve chronic pain associated with a variety of conditions (
https://ibn.fm/ZRbn6). Accordingly, Pure Extracts engages in three cannabis/hemp-related verticals that include in-house marketing for their own brands, converting raw biomass into marketable products, and providing white labeling services for brands looking to enter the rapidly growing market.
Functional mushrooms – another Pure Extracts vertical – are rapidly emerging in the collective awareness for their ability to combat illness, increase mental cognition and improve digestion. Varieties containing psilocybin, also known as “psychedelic” or “magic” mushrooms”, are currently being studied by prestigious research institutions like UC Berkeley as a possible treatment for depression, anxiety, PTSD, bipolar disorder, Alzheimer’s disease and addiction (
https://ibn.fm/BNc5a). Therapy options may be available in the near future as FDA approvals for their use in treatment-resistant depression are expected sometime in 2021 (
https://ibn.fm/et1aY). If this happens, demand for highly purified, pharma-grade, mushroom extracts has the potential to skyrocket.
Based in Pemberton, British Columbia, Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act on September 25, 2020. The Company engages in the cannabis and hemp industry through toll processing, white labeling, and developing its own private label products, in addition to expanding its business to include functional mushrooms. The Company has a fully-built CO2 extraction facility that complies with European Union GMP standards and intends to seek EU GMP certification in order to export its products to jurisdictions within Europe where such products are legal.
For more information, visit the company’s website at
www.PureExtractsCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at
https://ibn.fm/PULL
